Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and
efficacy of Relestat Ophthalmic Solution 0.05% in patients with allergic conjunctivitis who
are treated with Relestat as standard of care in clinical practice.